A flagship product of Generex Biotechnology Corporation - Oral-lyn™ - is an oral insulin spray for the treatment of diabetes.

Oral-lyn™, a liquid formulation of regular human insulin, is delivered to the buccal mucosa by way Generex's RapidMist™ device. Apparently, the absorption of Oral-lyn™ is limited to the mouth with no entry into the lungs.

Generex's Oral-lyn™ can be used as a preventative pharmacologic agent by people with pre-diabetes to delay the onset of diabetes and by patients with type-2 diabetes to delay the onset of insulin dependence and the complications associated with diabetes.

Morever, current trials are yielding promising results, as was recently published in Diabetes Technology & Therapeutics (article title: Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes):

The published conclusion is that regular insulin and Generex Oral-lyn had similar glucodynamic effects in subjects with Type-1 Diabetes Mellitus receiving twice-daily insulin analogue as baseline therapy.

Intensive monitoring and timely corrections with additional snacks, additional sc regular insulin, or Generex Oral-lyn(tm) puffs resulted in appropriate glycemic control as assessed by individual daily glycemic responses and especially, normal preprandial glycation decreased, but not significantly.

Oral-lyn™ is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes. Generex expects to commence Phase III trial of this product in the United States, Canada and Europe before the end of 2007.

Story and Photo Source: Generex Biotechnolgy Corporation